Autres langues BriaCell Therapeutics Corp.

Actions

BCT

CA1079303071

Recherche biotechnologique et médicale

Temps Différé Toronto S.E. Autres places de cotation 19:02:59 10/07/2026			Varia. 5j.	Varia. 1 janv.
5,460 ^CAD	+5,61%		+20,00%	-44,29%

07/07	BriaCell mandate des cabinets de conseil et de stratégie de marque en vue de la commercialisation potentielle du Bria-IMT	MT
25/06	BriaCell s'associe à Uneedle pour l'administration à grande échelle du Bria-IMT par micro-aiguilles	CI

Autres langues

07/07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT
07/07	BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
25/06	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT
25/06	BriaCell Therapeutics Inks MOU With Dutch Microneedle Company
25/06	BriaCell Therapeutics : Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)
25/06	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
09/06	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026
02/06	BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering
02/06	BriaCell Therapeutics Closes $4.7 Million Share Offering
02/06	BriaCell Therapeutics Announces Closing of Offering
01/06	BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting
01/06	BriaCell Presents Positive Clinical Data at ASCO 2026
01/06	BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million
01/06	BriaCell Therapeutics Prices $4.7 Million Share Offering
01/06	Briacell Therapeutics prices 1.45 million common shares at $3.25 per share
01/06	BriaCell Therapeutics Announces Pricing of Offering
26/05	Briacell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study of Bria-Imt Plus Immune Checkpoint Inhibitor in Metastatic Breast Cancer
26/05	BriaCell Receives DSMB Nod to Continue With Phase 3 Metastatic Breast Cancer Study
26/05	BriaCell Says Received Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
26/05	Briacell receives positive recommendation from data safety monitoring board (DSMB) for phase 3 study in metastatic breast cancer
26/05	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
22/05	BriaCell Says Presenting Posters, Publication-only Abstracts at ASCO 2026
22/05	BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
18/05	BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+
15/05	BriaCell Therapeutics Developing Ovarian Cancer Immunotherapy Candidate